PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
27 mars 2024 08h00 HE
|
PMV Pharmaceuticals, Inc.
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2...
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
18 mars 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation...
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29 févr. 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors...
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
26 févr. 2024 08h00 HE
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
18 janv. 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling...
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
05 janv. 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs)Michael...
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
09 nov. 2023 08h00 HE
|
PMV Pharmaceuticals, Inc.
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across...
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
12 oct. 2023 12h30 HE
|
PMV Pharmaceuticals, Inc.
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in...
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
11 oct. 2023 12h00 HE
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
20 sept. 2023 16h05 HE
|
PMV Pharmaceuticals, Inc.
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a...